1. T2DM Management

2. Program Overview

3. The Development of Basal Insulins

4. Continuum of Clinical Research: RCTs and RWE

5. BEGIN and EDITION Trials for Deg-100 and Gla-300

6. RWE for Gla-300: DELIVER Studies

7. DEVOTE Trial: Deg-100 vs Gla-100

8. Comparing PK/PD Data

9. Cannot Directly Compare BEGIN and EDITION Programs

10. BRIGHT: Head-to-Head Comparison of Gla-300 and Deg-100

11. BRIGHT: Study Endpoints and Glycemic Targets

12. BRIGHT: Baseline Characteristics

13. BRIGHT: Primary Endpoint: Glycemic Control

14. BRIGHT: FPG and SMBG Reduction

15. BRIGHT: 8-Point SMBG and Variability Profiles

16. BRIGHT: Anytime (24 h) Hypoglycemia

17. BRIGHT: Nocturnal (00:00–06:00 h) Hypoglycemia

18. BRIGHT: TEAEs

19. BRIGHT: Insulin Dosage and Body Weight Over 24 Weeks

20. BRIGHT: Results Summary

21. Conclusions

22. Abbreviations

23. Abbreviations (cont)